[go: up one dir, main page]

MX2020002251A - Compuestos espirociclicos y sus metodos de preparacion y uso. - Google Patents

Compuestos espirociclicos y sus metodos de preparacion y uso.

Info

Publication number
MX2020002251A
MX2020002251A MX2020002251A MX2020002251A MX2020002251A MX 2020002251 A MX2020002251 A MX 2020002251A MX 2020002251 A MX2020002251 A MX 2020002251A MX 2020002251 A MX2020002251 A MX 2020002251A MX 2020002251 A MX2020002251 A MX 2020002251A
Authority
MX
Mexico
Prior art keywords
preparation
methods
spirocyclic compounds
compounds
spirocyclic
Prior art date
Application number
MX2020002251A
Other languages
English (en)
Inventor
Daniel J Buzard
Cheryl A Grice
Todd K Jones
Olivia D Weber
Michael B Shaghafi
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of MX2020002251A publication Critical patent/MX2020002251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En la presente se proporcionan compuestos y composiciones útiles como moduladores de MAGL. Además, los compuestos y las composiciones de la presente son útiles para el tratamiento del dolor.
MX2020002251A 2017-08-29 2018-08-28 Compuestos espirociclicos y sus metodos de preparacion y uso. MX2020002251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29
PCT/US2018/048372 WO2019046318A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
MX2020002251A true MX2020002251A (es) 2020-07-20

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002251A MX2020002251A (es) 2017-08-29 2018-08-28 Compuestos espirociclicos y sus metodos de preparacion y uso.

Country Status (27)

Country Link
US (1) US11142526B2 (es)
EP (1) EP3675847B1 (es)
JP (1) JP7257387B2 (es)
KR (1) KR20200046061A (es)
CN (1) CN111050765B (es)
AU (1) AU2018323459A1 (es)
BR (1) BR112020004101A2 (es)
CA (1) CA3072923A1 (es)
CL (1) CL2020000462A1 (es)
CO (1) CO2020001724A2 (es)
CR (1) CR20200089A (es)
DO (1) DOP2020000039A (es)
EA (1) EA202090312A1 (es)
EC (1) ECSP20013337A (es)
ES (1) ES2952332T3 (es)
GE (2) GEAP202115281A (es)
IL (1) IL272580B (es)
JO (1) JOP20200023A1 (es)
MA (1) MA50041A (es)
MX (1) MX2020002251A (es)
NI (1) NI202000014A (es)
PE (1) PE20200664A1 (es)
PH (1) PH12020500372A1 (es)
SG (1) SG11202001022TA (es)
UA (1) UA126685C2 (es)
WO (1) WO2019046318A1 (es)
ZA (1) ZA202001208B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN111050765B (zh) 2017-08-29 2024-01-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
PE20200665A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
AU2020311584A1 (en) * 2019-07-09 2022-01-20 F. Hoffmann-La Roche Ag New heterocyclic compounds
EP4204420B1 (en) * 2020-08-26 2024-08-07 F. Hoffmann-La Roche AG Heterocyclic compounds useful as magl inhibitors
TWI904281B (zh) * 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
WO2023130023A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
US12378219B2 (en) 2022-05-04 2025-08-05 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368354A1 (en) * 2001-03-07 2003-12-10 Pfizer Products Inc. Modulators of chemokine receptor activity
JPWO2008023720A1 (ja) 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2011040905A1 (en) 2009-09-29 2011-04-07 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
ME02437B (me) 2009-10-23 2016-09-20 Janssen Pharmaceutica Nv Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
JP2013521290A (ja) 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション Ｍｇｌｕｒ２の正のアロステリックモジュレータ
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
MX350788B (es) * 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
SI2900669T1 (sl) 2012-09-25 2019-12-31 F. Hoffmann-La Roche Ag Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
HK1249101A1 (zh) 2015-07-31 2018-10-26 辉瑞公司 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
DK3436444T3 (da) 2016-03-31 2020-07-27 Takeda Pharmaceuticals Co Heterocyklisk forbindelse
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3043610A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Crystalline forms of a magl inhibitor
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US11273159B2 (en) 2016-11-16 2022-03-15 H. Lundbeck A/S Pharmaceutical formulations
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PE20200665A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
CN111050765B (zh) 2017-08-29 2024-01-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法

Also Published As

Publication number Publication date
JP7257387B2 (ja) 2023-04-13
US20200255427A1 (en) 2020-08-13
JOP20200023A1 (ar) 2020-02-02
EP3675847A1 (en) 2020-07-08
PE20200664A1 (es) 2020-06-11
ECSP20013337A (es) 2020-04-22
SG11202001022TA (en) 2020-03-30
AU2018323459A1 (en) 2020-02-20
BR112020004101A2 (pt) 2020-09-24
EP3675847B1 (en) 2023-07-12
US11142526B2 (en) 2021-10-12
CO2020001724A2 (es) 2020-02-28
NI202000014A (es) 2020-07-28
EA202090312A1 (ru) 2020-08-05
EP3675847A4 (en) 2021-01-06
CA3072923A1 (en) 2019-03-07
KR20200046061A (ko) 2020-05-06
JP2020532545A (ja) 2020-11-12
CN111050765A (zh) 2020-04-21
GEAP202115281A (en) 2021-08-10
PH12020500372A1 (en) 2020-12-07
MA50041A (fr) 2020-07-08
CR20200089A (es) 2020-04-08
IL272580A (en) 2020-03-31
IL272580B (en) 2022-09-01
CN111050765B (zh) 2024-01-02
RU2020107163A3 (es) 2022-03-15
RU2020107163A (ru) 2021-09-30
UA126685C2 (uk) 2023-01-11
ES2952332T3 (es) 2023-10-30
GEP20217327B (en) 2021-12-10
WO2019046318A1 (en) 2019-03-07
DOP2020000039A (es) 2020-08-31
EP3675847C0 (en) 2023-07-12
CL2020000462A1 (es) 2020-07-10
ZA202001208B (en) 2021-08-25

Similar Documents

Publication Publication Date Title
CL2020000463A1 (es) Compuestos espirocíclicos y sus métodos de preparación y uso.
CL2020000462A1 (es) Compuestos espirocíclicos y sus métodos de preparación y uso.
CO2019004945A2 (es) Inhibidores de la magl
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
ECSP19083923A (es) Inhibidores pirazólicos de magl
MX2020012158A (es) Inhibidores de magl.
CO2019005059A2 (es) Inhibidores de magl
CO2019005038A2 (es) Inhibidores de magl
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
CL2017003404A1 (es) Compuestos antibacterianos
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
MX394318B (es) Inhibidores pirazolicos de magl
CL2019002583A1 (es) Inhibidores duales de magl y faah.